Tremelimumab  (Synonyms: Ticilimumab; CP-675206)

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research^[1].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans^[1].
Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner^[1].
Tremelimumab enhances the IL-2 production in T-cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

745013-59-6

Liquid

Colorless to light yellow

[Tremelimumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Flow cytometry analysis of CTLA4 overexpression CHOK1 cells labelling CTLA4 with Tremelimumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
• 
  Immobilized CTLA-4 Protein, Human can bind Tremelimumab. The EC₅₀ for this effect is 1.69 ng/mL.

• [1]. Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76.  [Content Brief]